{
    "clinical_study": {
        "@rank": "43510", 
        "arm_group": [
            {
                "arm_group_label": "1(12.5\u33a0)", 
                "arm_group_type": "Experimental", 
                "description": "drug : 9 people, 43.75mg/12.5\u33a0\nplacebo : 3 people, 12.5\u33a0"
            }, 
            {
                "arm_group_label": "2(25\u33a0)", 
                "arm_group_type": "Experimental", 
                "description": "drug : 9 people, 87.5mg/25\u33a0\nplacebo : 3 people, 25\u33a0"
            }, 
            {
                "arm_group_label": "3(50\u33a0)", 
                "arm_group_type": "Experimental", 
                "description": "drug : 9 people, 175mg/50\u33a0\nplacebo : 3 people, 50\u33a0"
            }
        ], 
        "brief_summary": {
            "textblock": "Study of the Safety, tolerability and pharmacokinetics with single dose of donepezil patch\n      in healthy male subjects."
        }, 
        "brief_title": "A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI : more than 20 \u338f/\u33a1, less than 26 \u338f/\u33a1\n\n          -  Systolic blood pressure : more than 90, less than 140 (mmHg)\n\n          -  Diastolic blood pressure : more than 60, less than 100 (mmHg)\n\n        Exclusion Criteria:\n\n          -  Evidence of clinically significant, severe, active, or unstable gastrointestinal,\n             renal,hepatic, respiratory, hematological, endocrine, or cardiovascular system\n             disease.\n\n          -  A history of skin disease or skin graft\n\n          -  Hypersensitivity to donepezil or piperidine derivatives or any of the excipients.\n\n          -  A known or suspected history of drug or alcohol dependency or abuse\n\n          -  Patients who have participated in another clinical study within 60 days.\n\n          -  Whole blood within 60 days, apheresis within 30 days, transfusion within 30 days\n\n          -  Heavy caffeine intake(more than 5 units/day)\n\n          -  Heavy alcohol intake(more than 21 units/week)\n\n          -  Heavy smoker(more than 10 cigarette/day)\n\n          -  Abnormal clinical laboratory values which are judged clinically significant by the\n             investigator.\n\n          -  Any condition that would make the patient or the caregiver, in the opinion of the\n             investigator, unsuitable for the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860625", 
            "org_study_id": "IPI-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1(12.5\u33a0)", 
                    "2(25\u33a0)", 
                    "3(50\u33a0)"
                ], 
                "intervention_name": "Donepezil patch", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1(12.5\u33a0)", 
                    "2(25\u33a0)", 
                    "3(50\u33a0)"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Donepezil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "ASAN Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "evaluation item\nadverse event\nelectrocardiographie\nvital sign\nphysical examination\nurine, blood test\nskin irritation", 
            "measure": "safety and tolerability evaluation", 
            "safety_issue": "No", 
            "time_frame": "-1d~20d"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860625"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "evaluation item : donepezil conc.\nevaluation variable\nAUC last, AUC0-\u221e, Cmax, tmax, t1/2\u03b2, CL/F", 
            "measure": "pharmacokinetics characteristic evaluation", 
            "safety_issue": "No", 
            "time_frame": "1d 0h(before administration), (after administration)4h, 8h, 12h, 24h, 48h, 70h, 72h, 74h, 76h, 80h, 96h, 120h, 144h, 168h, 216h, 264h, 312h"
        }, 
        "source": "Icure Pharmaceutical Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Icure Pharmaceutical Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}